Hot Pursuit     05-Dec-24
Auro Pharma arm gets USFDA nod for Pazopanib tabs
Aurobindo Pharma announced that its wholly owned subsidiary company, Eugia Pharma Specialities received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Pazopanib Tablets.
The approved drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Votrient Tablets, of Novartis Pharmaceuticals Corporation.

Pazopanib Tablets, is indicated for the treatment of adults with advanced renal cell carcinoma (RCC), and advanced soft tissue sarcoma (STS) who have received prior chemotherapy.

The product is expected to be launched in Q4 FY25. The approved product has an estimated market size of $106 million for the twelve months ending October 2024, according to IQVIA.

This is the 179 th ANDA approval (including 8 tentative approvals received) out of Eugia Pharma Specialities Group (EPSG) facilities, manufacturing both oncology oral and sterile specialty products.

Aurobindo Pharma is principally engaged in manufacturing and marketing of active pharmaceutical ingredients, generic pharmaceuticals and related services.

The pharma major reported 7.95% rise in consolidated net profit to Rs 817.38 crore on a 6.93% increase in revenue from operations to Rs 7,646.21 crore in Q2 FY25 over Q2 FY24.

Shares of Aurobindo Pharma declined 0.98% to Rs 1,245.70 on the BSE.

Previous News
  Auro Pharma Q3 PAT slides 10% YoY to Rs 846 crore
 ( Hot Pursuit - 07-Feb-25   12:47 )
  Aurobindo Pharma consolidated net profit declines 9.66% in the December 2024 quarter
 ( Results - Announcements 07-Feb-25   07:32 )
  Board of Aurobindo Pharma approves acquisition of 26% stake in a solar energy company
 ( Corporate News - 06-Feb-25   20:22 )
  Board of Aurobindo Pharma approves acquisition of 80% stake in Tergene Biotech
 ( Corporate News - 06-Feb-25   20:19 )
  Apitoria Pharma's Unit 2 completes USFDA inspection
 ( Corporate News - 28-Jan-25   12:15 )
  Aurobindo Pharma Ltd rises for third straight session
 ( Hot Pursuit - 20-Jan-25   13:06 )
  Aurobindo Pharma to table results
 ( Corporate News - 17-Jan-25   18:01 )
  Aurobindo Pharma Ltd slips for fifth straight session
 ( Hot Pursuit - 08-Jan-25   13:35 )
  Aurobindo Pharma Ltd up for third straight session
 ( Hot Pursuit - 31-Dec-24   13:05 )
  CuraTeQ Biologics receives UK MHRA approval for oncology biosimilar Bevqolva
 ( Corporate News - 23-Dec-24   16:13 )
  Auro Pharma gets UK MHRA nod for cancer drug
 ( Hot Pursuit - 21-Dec-24   15:20 )
Other Stories
  Genesys Intl Q3 PAT climbs 32% YoY to Rs 21 cr
  15-Feb-25   12:15
  PTC Industries Q3 PAT spurts 76% YoY to Rs 14 cr
  15-Feb-25   11:34
  RVNL Q3 PAT slides 13% YoY to Rs 311 crore
  15-Feb-25   10:47
  BHEL bags Rs 6,700 crore power project from Singareni Collieries
  15-Feb-25   09:48
  Mahindra & Mahindra's electric SUVs see 30,179 bookings on day 1
  15-Feb-25   09:32
  Reliance Industries acquires Lakadia B Power Transmission
  15-Feb-25   09:21
  Ethos rises after Q3 PAT climbs 15% YoY to Rs 29 cr
  14-Feb-25   15:12
  Anupam Rasayan rises after Q3 PAT zooms 108% YoY to Rs 54 cr
  14-Feb-25   15:03
  FACT tumbles after PAT falls nearly 74% in Q3 FY25 to Rs 8 crore
  14-Feb-25   15:02
  Concord Biotech Ltd leads losers in 'A' group
  14-Feb-25   15:00
Back Top